Judes Poirier
#141,337
Most Influential Person Now
Researcher
Judes Poirier's AcademicInfluence.com Rankings
Judes Poiriercomputer-science Degrees
Computer Science
#6800
World Rank
#7165
Historical Rank
Machine Learning
#2324
World Rank
#2352
Historical Rank
Artificial Intelligence
#2598
World Rank
#2639
Historical Rank
Database
#3878
World Rank
#4034
Historical Rank
Download Badge
Computer Science
Judes Poirier's Degrees
- PhD Computer Science Université de Montréal
- Masters Artificial Intelligence McGill University
- Bachelors Computer Science Université de Montréal
Similar Degrees You Can Earn
Why Is Judes Poirier Influential?
(Suggest an Edit or Addition)Judes Poirier's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Apolipoprotein E polymorphism and Alzheimer's disease (1993) (1001)
- Apolipoprotein E in animal models of CNS injury and in alzheimer's disease (1994) (681)
- Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) (2001) (627)
- Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. (1995) (613)
- Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. (1991) (388)
- Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats (1993) (355)
- The ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β‐amyloid (2000) (350)
- Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat (1990) (343)
- Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein (1997) (336)
- Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. (1999) (267)
- ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINE (1985) (245)
- Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. (1999) (241)
- The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease* (2005) (235)
- Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. (1995) (225)
- The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease (1998) (206)
- Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease (1998) (193)
- Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain (2000) (185)
- Apolipoprotein E and Alzheimer's Disease A Role in Amyloid Catabolism (2000) (169)
- Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. (1999) (168)
- Increased Levels of Apolipoprotein D in Cerebrospinal Fluid and Hippocampus of Alzheimer's Patients (1998) (167)
- Olfactory identification as a potential marker of presymptomatic Alzheimer's disease (2013) (166)
- Sports concussions and aging: a neuroimaging investigation. (2012) (165)
- Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. (2003) (164)
- Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease (2005) (159)
- Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies (1994) (152)
- APOE and cholesterol homeostasis in Alzheimer's disease. (2010) (149)
- Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. (1998) (145)
- The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. (2000) (135)
- Altered bidirectional plasticity and reduced implicit motor learning in concussed athletes. (2012) (131)
- Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent (1999) (131)
- Increased caveolin-1 expression in Alzheimer’s disease brain (2004) (116)
- Differential progression of Dark Neuron and Fluoro-Jade labelling in the rat hippocampus following pilocarpine-induced status epilepticus (2000) (112)
- Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens. (1985) (110)
- Cholesterol and APOE genotype interact to influence Alzheimer disease progression (2004) (100)
- Apolipoprotein E, Plaques, Tangles and Cholinergic Dysfunction in Alzheimer's Disease a (1996) (99)
- Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain. (2001) (97)
- The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. (1985) (97)
- Cloning of hippocampal poly(A) RNA sequences that increase after entorhinal cortex lesion in adult rat. (1991) (94)
- Apolipoprotein E, synaptic plasticity and Alzheimer's disease. (1995) (93)
- Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease (2014) (92)
- Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy a (1996) (89)
- Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. (2002) (88)
- Brain lipoprotein metabolism and its relation to neurodegenerative disease. (1999) (85)
- Odor identification as a biomarker of preclinical AD in older adults at risk (2017) (84)
- β‐Amyloid Peptides Increase the Binding and Internalization of Apolipoprotein E to Hippocampal Neurons (1998) (80)
- Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. (1999) (79)
- Effect of MPTP and l‐Deprenyl on Antioxidant Enzymes and Lipid Peroxidation Levels in Mouse Brain (1995) (76)
- Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice (1999) (74)
- HSV-1 in brain and risk of Alzheimer's disease (1998) (73)
- Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study (2019) (72)
- Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment (2002) (71)
- Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion. (1999) (71)
- The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease (1999) (69)
- Further evidence for a synergistic association between APOEɛ4 and BCHE-K in confirmed Alzheimer’s disease (1999) (68)
- INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease (2019) (67)
- Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. (1999) (66)
- Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: analysis of learning strategies in three versions of the task (2002) (65)
- Apolipoprotein E in the brain and its role in Alzheimer's disease. (1996) (65)
- Altered Gene Expression in Alzheimer's Disease Brain Tissue (1989) (63)
- A role for caveolin‐1 in post‐injury reactive neuronal plasticity (2005) (62)
- DEBRISOQUINE METABOLISM IN PARKINSONIAN PATIENTS TREATED WITH ANTIHISTAMINE DRUGS (1987) (61)
- Apolipoprotein C-I Expression in the Brain in Alzheimer's Disease (2001) (60)
- The cholesterol-lowering drug Probucol increases apolipoprotein e production in the hippocampus of aged rats: implications for Alzheimer’s disease (2003) (58)
- Entorhinal cortex lesion induces differential responses in [125I]insulin-like growth factor I, [125I]insulin-like growth factor II and [125I]insulin receptor binding sites in the rat hippocampal formation (1993) (58)
- APOE2 Is Associated with Spatial Navigational Strategies and Increased Gray Matter in the Hippocampus (2016) (58)
- The Caveolin Scaffolding Domain Modifies 2-Amino-3-hydroxy-5-methyl-4-isoxazole Propionate Receptor Binding Properties by Inhibiting Phospholipase A2 Activity* (2004) (57)
- CHOLESTEROL TRANSPORT AND SYNTHESIS IN SPORADIC ALZHEIMER'S DISEASE (2005) (56)
- Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. (1999) (56)
- Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD). (2016) (55)
- Apolipoprotein E and Low‐Density Lipoprotein Binding and Internalization in Primary Cultures of Rat Astrocytes: Isoform‐Specific Alterations (1996) (54)
- Selective alterations of RNA in rat hippocampus after entorhinal cortex lesioning. (1990) (52)
- A catalyst function for MPTP in superoxide formation. (1985) (51)
- Motor system alterations in retired former athletes: the role of aging and concussion history (2013) (51)
- A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
- Biomarkers of dementia in obstructive sleep apnea. (2018) (50)
- Amyloid β peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats (2001) (50)
- Influence of the apolipoprotein E ε4 allele on human embryonic development (2002) (48)
- HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study (2014) (48)
- Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer’s disease (2008) (46)
- ApoE associated with lipid has a reduced capacity to inhibit β‐amyloid fibril formation (1998) (46)
- Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study (2011) (46)
- Multiple cholinergic markers are unexpectedly not altered in the rat dentate gyrus following entorhinal cortex lesions (1994) (44)
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
- Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease (2018) (43)
- Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer’s Disease (2017) (43)
- A polymorphism in lipoprotein lipase affects the severity of Alzheimer's disease pathophysiology (2006) (42)
- Function and Comorbidities of Apolipoprotein E in Alzheimer's Disease (2011) (42)
- 1-Methyl-4-phenyl-pyridinium-induced inhibition of nicotinamide adenosine dinucleotide cytochrome c reductase (1985) (41)
- The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study (2019) (40)
- A role for lipoprotein lipase during synaptic remodeling in the adult mouse brain (2004) (40)
- Superoxide Dismutase Expression in Parkinson's Disease (1994) (39)
- Normalization of gene expression using SYBR green qPCR: A case for paraoxonase 1 and 2 in Alzheimer's disease brains (2011) (38)
- Alterations in cholesterol metabolism–related genes in sporadic Alzheimer's disease (2018) (38)
- Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology (2006) (37)
- Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: role of the astroglial response (2005) (36)
- A deficit in astroglial organization causes the impaired reactive sprouting in human apolipoprotein E4 targeted replacement mice (2006) (36)
- Erythrocyte antioxidant activity in human patients with Parkinson's disease (1987) (34)
- Polymorphisms at the Paraoxonase 1 L55M and Q192R Loci Affect the Pathophysiology of Alzheimer’s Disease: Emphasis on the Cholinergic System and Beta-Amyloid Levels (2008) (33)
- Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression (2019) (33)
- Involvement of paraoxonase 1 genetic variants in Alzheimer’s disease neuropathology (2009) (33)
- Combined in situ hybridization and immunocytochemistry in the assay of pharmacological effects on tyrosine hydroxylase mRNA concentration. (1989) (33)
- Alzheimer's disease: current knowledge, management and research. (1997) (33)
- Profiles of β-Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE ε4 Status: Impact for Risk and Progression of Alzheimer Disease (2018) (31)
- Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities (2017) (31)
- Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. (1998) (31)
- AMPA receptor regulation and LTP in the hippocampus of young and aged apolipoprotein E-deficient mice (2001) (31)
- APOEε4 potentiates the relationship between amyloid-β and tau pathologies (2020) (31)
- Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer’s disease (2015) (30)
- The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder (2017) (30)
- Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. (2016) (30)
- Influence of the apolipoprotein E epsilon4 allele on human embryonic development. (2002) (30)
- Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis (2018) (29)
- Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease (2018) (28)
- Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases. (2014) (28)
- Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. (2020) (28)
- TLR4 Gene Expression and Pro-Inflammatory Cytokines in Alzheimer's Disease and in Response to Hippocampal Deafferentation in Rodents. (2018) (28)
- BDNF Val66Met Polymorphism Interacts with Sleep Consolidation to Predict Ability to Create New Declarative Memories (2016) (27)
- HLA class I, II & III genes in confirmed late-onset Alzheimer’s disease (2001) (26)
- Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults (2022) (26)
- Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia (2016) (25)
- Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
- Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease (2021) (25)
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study (2019) (24)
- The effect of L-deprenyl, D-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity. (1997) (24)
- Longitudinal Basal Forebrain Degeneration Interacts with TREM2/C3 Biomarkers of Inflammation in Presymptomatic Alzheimer's Disease (2020) (24)
- Environment, Genetics and Idiopathic Parkinson's Disease (1991) (23)
- Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation (2019) (23)
- Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. (1999) (23)
- Morphometric network differences in ageing versus Alzheimer's disease dementia. (2020) (23)
- Acute and long-term associations between ApoE genetic polymorphism, cortisol levels, and declarative memory performance in older adults (2008) (22)
- Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease (2004) (22)
- Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults (2020) (22)
- The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain (2012) (21)
- The apoE receptor apoER2 is involved in the maintenance of efficient synaptic plasticity (2005) (21)
- Isoprenoids and tau pathology in sporadic Alzheimer's disease (2018) (20)
- Pro-inflammatory cytokines modulate glial apolipoprotein E secretion. (2008) (20)
- Non‐steroidal anti‐inflammatory drugs mediate increased in vitro glial expression of apolipoprotein E protein (2003) (20)
- Proximity to Parental Symptom Onset and Amyloid-&bgr; Burden in Sporadic Alzheimer Disease (2018) (19)
- Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. (2016) (19)
- Polymorphism of the 5-HT2A Receptor Gene: Association with Stress-Related Indices in Healthy Middle-Aged Adults (2007) (19)
- Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” Who may benefit from disease-modifying studies in Alzheimer's disease? (2009) (19)
- Biological changes associated with healthy versus pathological aging: A symposium review (2009) (17)
- Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease (2018) (16)
- Differential regulation of ABCA1 and ABCG1 gene expressions in the remodeling mouse hippocampus after entorhinal cortex lesion and liver-X receptor agonist treatment (2014) (16)
- Modulation of γ-actin and α1-tubulin expression by corticosterone during neuronal plasticity in the hippocampus (1992) (16)
- Current and future management of Alzheimer’s disease (2008) (16)
- Cerebral white matter diffusion properties and free‐water with obstructive sleep apnea severity in older adults (2020) (15)
- L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. (1997) (15)
- Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease? (1993) (15)
- Prevalence and family-related factors associated with suicidal ideation, suicide attempts, and self-injury in children aged 9 to 10 years (2020) (14)
- Impact of BDNF Val66Met polymorphism on olfactory functions of female concussed athletes (2015) (14)
- Pharmacogenetics of Psychotropic Drugs: Apolipoprotein E as a marker in the treatment of Alzheimer's disease (2002) (14)
- Apolipoprotein E: A Novel Therapeutic Target for the Treatment of Alzheimer’s Disease (2002) (14)
- Disconnection Between Self-Reported and Objective Cognitive Impairment in Obstructive Sleep Apnea. (2019) (13)
- Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer’s Disease (2017) (13)
- [3H]Phorbol ester binding sites and neuronal plasticity in the hippocampus following entorhinal cortex lesions (1993) (13)
- Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. (2022) (12)
- Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease (2021) (12)
- CDK5RAP2 gene and tau pathophysiology in late-onset sporadic Alzheimer's disease (2017) (12)
- Polymorphism of the 5-HT 2 A receptor gene : Association with stress-related indices in healthy middle-aged adults (2007) (12)
- Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology (2019) (12)
- Apolipoprotein E4 and Cholinergic Dysfunction in Alzheimer’s Disease (1994) (11)
- Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease (2015) (11)
- Altered declarative memory in introverted middle-aged adults carrying the BDNF val66met allele (2013) (10)
- Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
- Epistasis analysis links immune cascades and cerebral amyloidosis (2015) (10)
- Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer’s Disease Pathology (2015) (10)
- Apolipoprotein E4, Cholinergic Integrity, Synaptic Plasticity and Alzheimer’s Disease (1996) (10)
- CHAPTER 11 – Adrenal glucocorticoids as modulators of hippocampal neuron survival, repair and function in the aged rat (1993) (9)
- Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease (2021) (9)
- MPTP potentiates iron-induced lipid peroxidation without the involvement of free radicals derived from oxygen. (1987) (9)
- BDNF Val66Met Polymorphism Influences Visuomotor Associative Learning and the Sensitivity to Action Observation (2016) (9)
- Creation of an Open Science Dataset from PREVENT-AD, a Longitudinal Cohort Study of Pre-symptomatic Alzheimer’s Disease (2020) (8)
- A PROGRAM OF PRE-SYMPTOMATIC EVALUATION OF EXPERIMENTAL OR NOVEL TREATMENTS FOR ALZHEIMER'S DISEASE (PREVENT-AD): DESIGN, METHODS, AND PERSPECTIVES (2014) (8)
- Association of PPP2R1A with Alzheimer's disease and specific cognitive domains (2019) (8)
- Cholesterol transport and synthesis are compromised in the brain in sporadic Alzheimer’s disease: from risk factors to therapeutic targets (2002) (8)
- 54-1 Advances in the diagnosis of Alzheimer's disease (1997) (8)
- Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress (2008) (7)
- Apolipoprotein E and neuronal plasticity following experimental de-afferentation and in Alzheimer's disease. (1998) (7)
- Subtypes of functional brain connectivity as early markers of neurodegeneration in Alzheimer’s disease (2017) (7)
- Apoptosis techniques and protocols (1997) (7)
- Entorhinal Cortex Lesions Transiently Alter Glucocorticoid but Not Mineralocorticoid Receptor Gene Expression in the Rat Hippocampus (1993) (7)
- Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease Vascular risk factors and functional connectivity changes (2021) (7)
- CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem (2018) (7)
- Regulation of 1,4,5-IP3, 1,3,4,5-IP4 and IP6 binding sites following entorhinal cortex lesions in rat brain (1994) (7)
- Could Lipoprotein Lipase Play a Role in Alzheimer's Disease? (2004) (6)
- Statin, a Marker of Cell Cycle Arrest, Is Overexpressed during the Early Phase of Delayed NMDA Toxicity in Hippocampal Cell Cultures (1994) (6)
- INTREPAD (2019) (6)
- ASSOCIATION OF OLFACTORY PERFORMANCE AND HIPPOCAMPAL VOLUME IN PERSONS AT RISK OF ALZHEIMER'S DEMENTIA (2014) (6)
- 14 - Alteration of Hippocampal RNA Prevalence in Response to Deafferentation (1991) (6)
- Association between BDNF Polymorphism and Hypothalamic-Pituitary-Adrenal Activity in Later Adulthood (2019) (5)
- Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates (2017) (5)
- Effect of the MAO‐B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain (1998) (5)
- Astroglial Gene Expression in the Hippocampus Following Partial Deafferentation in the Rat and in Alzheimer’s Disease (1990) (5)
- A putative role for PCSK9 in synaptic remodelling and plasticity in response to brain injury: implications for Alzheimer's disease (2011) (5)
- Modulation of gamma-actin and alpha 1-tubulin expression by corticosterone during neuronal plasticity in the hippocampus. (1992) (5)
- Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease (2020) (4)
- AT(N) predicts near-term development of Alzheimer's disease symptoms in unimpaired older adults (2022) (4)
- The risk of developing Alzheimer's disease associated with the APOE promoter polymorphisms (1999) (4)
- Apolipoprotein E and Alzheimer's disease (1995) (4)
- No apparent effect of naproxen on CSF markers of innate immune activation (2019) (4)
- Pathophysiology and Biochemical Mechanisms Involved in MPTP‐Induced Parkinsonism (1987) (4)
- Effects on Decline or Deterioration (1997) (3)
- Outcome Variables in Presymptomatic Individuals at Higher Risk of Developing Alzheimer Disease (1996) (3)
- Apolipoprotein E receptors and amyloid expression are modulated in an apolipoprotein E–dependent fashion in response to hippocampal deafferentation in rodent (2007) (3)
- Putative Links Between Some of the Key Pathological Features of the Alzheimer's Brain (1998) (3)
- Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer’s disease, irrespective of fibrillar amyloid-beta pathology (2020) (3)
- Altered Episodic Memory in Introverted Young Adults Carrying the BDNFMet Allele (2016) (3)
- LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY (2017) (3)
- Increased levels of statin, a marker of cell cycle arrest, in response to hippocampal neuronal injury. (1995) (2)
- HMG-CoA reductase as a risk factor and modulator of Alzheimer pathology (2010) (2)
- Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum (2021) (2)
- Apolipoprotein E Uptake is Increased by Beta-Amyloid Peptides and Reduced by Blockade of the LDL Receptor (1996) (2)
- Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition. (2022) (2)
- Aβ 34 is a BACE 1-derived degradation intermediate associated with amyloid clearance and Alzheimer ’ s disease progression (2019) (2)
- APOE as therapeutic target for the treatment of Alzheimer's disease (2000) (2)
- Nicotinic acetylcholine receptors are decreased in rat dentate gyrus following entorhinal cortex lesions (1992) (2)
- Cholesterol Transport and Production in Alzheimer's Disease (2008) (2)
- Social isolation is linked to classical risk factors of Alzheimer’s disease-related dementias (2021) (2)
- Phospholipase A2 activity is decreased selectively in the hippocampus of aged apolipoprotein E deficient mice (2000) (2)
- CNTN5 is associated with disease risk and pathology throughout the Alzheimer’s disease continuum (2021) (2)
- Bilingualism is associated with lower cognitive decline and with lower levels of AD biomarkers in a cognitively unaffected cohort (2021) (1)
- 296 Neurobiology of apolipoprotein E: A role in synaptic plasticity and integrity in the injured CNS and in Alzheimer's disease (1996) (1)
- EARLY INCREASE IN TAU-PET SIGNAL IS ASSOCIATED WITH Aβ BURDEN, CSF P-TAU LEVELS AND COGNITION IN COGNITIVELY NORMAL LATE-MIDDLE-AGED ADULTS (2018) (1)
- ApoE4 associated with higher tau accumulation independent of amyloid burden (2020) (1)
- ISOPRENOIDS PATHWAY, TAU PHOSPHORYLATION AND ALZHEIMER’S DISEASE (2017) (1)
- CSF apolipoprotein B is associated with early tau pathology and selective activation of a cytokine cascade in cognitively unaffected subjects with a parental history of Alzheimer’s disease (2021) (1)
- CSF MARKERS OF INFLAMMATION AND ALZHEIMER'S DISEASE PATHOGENESIS IN THE COGNITIVELY INTACT PREVENT-AD COHORT (2016) (1)
- APOE alleles are associated with sex-specific structural differences in brain regions affected in Alzheimer’s disease and related dementia (2022) (1)
- Bundle-specific associations between white matter microstructure and Aβ and tau pathology at their connecting cortical endpoints in older adults at risk of Alzheimer’s disease (2020) (1)
- EARLY INCREASE IN TAU-PET SIGNAL IS ASSOCIATED WITH Aβ BURDEN, CSF P-TAU LEVELS AND COGNITION IN COGNITIVELY NORMAL LATE-MIDDLE-AGED ADULTS (2018) (1)
- APOE ɛ2 vs APOE ɛ4 dosage shows sex-specific links to hippocampus-default network subregion co-variation (2022) (1)
- CHARACTERIZATION OF pADHC‐9: A POLY(A)RNA SEQUENCE OVEREXPRESSED IN ALZHEIMER'S DISEASE HIPPOCAHPUS (1988) (1)
- Apolipoprotein E4 and Cholinergic Activity in Alzheimer’s Disease (1997) (1)
- Mapping the progression of CSF and imaging biomarkers in “at-risk” healthy subjects: The prevent-ad program (2015) (1)
- ABNORMAL CHOLESTEROL PROCESSING IN ALZHEIMER ’ S DISEASE PATIENT ’ S FIBROBLASTS (2004) (1)
- Herpes Simplex Virus Type 1 in the Brain, Apolipoprotein E Genotype and Alzheimer’s Disease (2020) (1)
- Central auditory processing in individuals at risk for Alzheimer’s dementia (2015) (1)
- Butyrylcholinesterase pharmacogenomics in mild cognitive impairment (2010) (1)
- CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer’s disease (2021) (1)
- MOVING AWAY FROM SINGLE AD-SIGNATURE ROI: ASSESSING THE RELATIONSHIP BETWEEN WHOLE-BRAIN GRAY MATTER PATTERN, AD PATHOLOGY, AND COGNITION IN HEALTHY ELDERLY AT RISK OF AD (2017) (0)
- Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease (2022) (0)
- A blood cholesterol polygenic score in two independent AD cohorts (2020) (0)
- Apolipoprotein B gene regulation under healthy and neuropathological conditions (2021) (0)
- LONGITUDINAL COLLECTION OF CEREBROSPINAL FLUID IN RATS: A MINIMALLY INVASIVE METHOD (2014) (0)
- VASCULAR MEDICAL TREATMENTS INFLUENCE THE ASSOCIATION BETWEEN VASCULAR BURDEN AND AMYLOID PATHOLOGY IN ASYMPTOMATIC INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE (2019) (0)
- Elevated tau‐PET signal predicts near‐term conversion to mild cognitive impairment in cognitively unimpaired older adults (2022) (0)
- Functional brain network subtypes are associated with Alzheimer's disease biomarkers in an aging, high-risk, cognitively normal cohort: The prevent-alzheimer's disease study (2015) (0)
- Apolipoprotein E4: From synaptic remodeling to genetic risk factor in both familial and sporadic Alzheimer’s disease (2006) (0)
- 24 Apolipoprotein E4 modulates cholinergic activity and cholinergic drug responsiveness in Alzheimer's disease but demonstrates impaired regulation in vivo (1996) (0)
- Vascular burden is associated with a decline in default-mode and global resting-state functional connectivity in individuals at risk for Alzheimer’s disease (2020) (0)
- 3-hydroxymethylglutaryl-coenzyme-a reductase et diagnostic et pronostic de la demence (2002) (0)
- Spatial Extent of Amyloid-β Levels and Associations with Alzheimer’s Disease Biomarkers (2021) (0)
- ASSESSING THE IMPACT OF INFLAMMATION ON LIMBIC CIRCUITRY AND ITS ROLE IN DEPRESSION IN OLDER ADULTS (2017) (0)
- Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer’s Disease Pathology (2015) (0)
- HIGH CSF TAU IS RELATED TO REDUCED HIPPOCAMPAL VOLUME AND SUBJECTIVE COGNITIVE DECLINE IN HEALTHY ELDERLY WITH AMYLOID PATHOLOGY (2016) (0)
- Potential of ad biomarkers to reveal the presymptomatic disease process and the effects of treatments that may retard it (2015) (0)
- The interplay between functional MRI measures of episodic memory and CSF measures of tau in healthy adults at risk of Alzheimer’s Disease (2022) (0)
- munoassays for the clinical diagnostic work-up of AD. P4-069 DEVELOPMENT OFA PROCESS TO DISCLOSE AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL OLDER ADULT RESEARCH PARTICIPANTS (2014) (0)
- Pro-Inflammatory Cytokines and Anti-Inflammatory Drugs Modulate Glial Expression of Apolipoprotein E Protein (2013) (0)
- Author/Subject Indexes (1993) (0)
- YEARS TO PARENTAL SYMPTOM ONSET PREDICTS AMYLOID BURDEN IN HEALTHY ELDERLY WITH A PARENTAL HISTORY OF SPORADIC ALZHEIMER’S DISEASE (2017) (0)
- 331 Apolipoprotein E4 modulate cholinergic activity in Alzheimer's disease and beta-amyloid 1–40 and 25–35 modulate apolipoprotein E metabolism in primary neuronal cell culture (1996) (0)
- THE EFFECT OF LUMBAR PUNCTURE ON THE RETENTION OF THE PREVENT-AD COHORT AD (2016) (0)
- Cerebrospinal fluid ad biomarkers predict poorer cognitive performance in a cognitively intact cohort at risk of Alzheimer’s dementia: The prevent-ad program (2015) (0)
- Poster Sessions Wednesday/Thursday (2019) (0)
- IDENTIFICATION OF NOVEL GENETIC RISK VARIANTS FOR ALZHEIMER’S DISEASE IN THE HMGCR GENE LOCUS (2017) (0)
- THE IMPACT OF TSPO RS6971 POLYMORPHISM IN A CANADIAN NEUROIMAGING STUDY OF NEUROINFLAMMATION (2018) (0)
- GENOME-WIDE ASSOCIATION STUDY USING ALZHEIMER-RELATED PATHOLOGICAL BIOMARKERS (2014) (0)
- SREBF2 POLYMORPHISMS AND EXPRESSION LEVELS CORRELATE WITH ALZHEIMER’S DISEASE NEUROPATHOLOGY (2017) (0)
- LONGITUDINAL COLLECTION OF CEREBROSPINAL FLUID IN RATS: A MINIMALLY INVASIVE METHOD (2014) (0)
- LDLR, VLDLR and APOBR in the pathophysiology of sporadic Alzheimer’s disease (2022) (0)
- Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer Disease using Cholinomimetic Agents (2015) (0)
- Both Irreversible Neuronal Death and Reversible Neuronal Stress Are Associated with Increased Levels of Statin, a Marker of Cell Cycle Arrest (1997) (0)
- Plasma p‐tau231 in the Alzheimer’s disease continuum: A multi‐cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application (2021) (0)
- Olfactory identification is associated with CSF tau/abeta42 ratios in cognitively normal adults at high risk of Alzheimer's disease (2015) (0)
- CANDIDATE GENE STUDIES AND GWAS SUGGEST SUBSTANTIAL GENETIC INFLUENCE ON DEFICITS IN OLFACTORY IDENTIFICATION AMONG PERSONS AT RISK OF AD (2017) (0)
- Elevated tau‐PET signal predicts near‐term conversion to mild cognitive impairment in cognitively unimpaired older adults (2022) (0)
- Macrophage Scavenger Receptor 1 in the CSF pre‐symptomatic with a parental history of AD and in the cortex of autopsy‐confirmed Alzheimer’s Disease cases. (2022) (0)
- DEAFFERENTATION IN THE RAT AND IN ALZHEIMER'S DISEASE (1990) (0)
- The Canadian Coalition for Seniors’ Mental Health (CCSMH) and Canadian Academy of Geriatric Psychiatry (CAGP) Joint Scientific Meeting (2014) (0)
- PREDICTION OF BRAIN AGE USING RESTING-STATE FUNCTIONAL CONNECTIVITY REVEALS ACCELERATED AGING IN THE PRECLINICAL PHASE OF AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE, IRRESPECTIVE OF AMYLOID PATHOLOGY (2019) (0)
- PREDICTION OF BRAIN AGE USING RESTING-STATE FUNCTIONAL CONNECTIVITY REVEALS ACCELERATED AGING IN THE PRECLINICAL PHASE OF AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE, IRRESPECTIVEOF AMYLOID PATHOLOGY (2019) (0)
- GENETIC AND ENVIRONMENTAL FACTORS ARE DIFFERENTIALLY RELATED TO Aβ BURDEN IN THE PRESYMPTOMATIC PHASE OF AUTOSOMAL DOMINANT AND SPORADIC ALZHEIMER’S DISEASE (2018) (0)
- Pharmacogenomic approaches to the treatment of sporadic Alzheimer’s disease (2020) (0)
- Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer’s Disease (2023) (0)
- ASSOCIATION OF OLFACTORY PERFORMANCE AND HIPPOCAMPAL VOLUME IN PERSONS AT RISK OF ALZHEIMER'S DEMENTIA (2014) (0)
- Distinct changes in morphometric networks in aging versus Alzheimer’s disease dementia (2019) (0)
- APOLIPOPROTEIN E 4 AND CHOLINERGIC ACTIVITY IN ALZHEIMER ' S DISEASE (0)
- MOVING AWAY FROM SINGLE AD-SIGNATURE ROI: ASSESSING THE RELATIONSHIP BETWEEN WHOLE-BRAIN GRAY MATTER PATTERN, AD PATHOLOGY, AND COGNITION IN HEALTHY ELDERLY AT RISK OF AD (2017) (0)
- Open science datasets from PREVENT‐AD, a longitudinal cohort of pre‐symptomatic Alzheimer’s disease (2021) (0)
- [ 125 I]IGF I, [ 125 I]IGF II and [ 125 I]Insulin Receptor Binding Sites in the Rat Hippocampal Formation: Topographic Distribution and Response to Entorhinal Ablation (1993) (0)
- CLINICAL MANIFESTATIONS AND WHITE MATTER CHANGES IN GENE MUTATED EARLY ONSETALZHEIMER’S DISEASE (2018) (0)
- Cerebral expression of APOE and apoc-I in Alzheimer's disease in relation to ϵ4 and H2 polymorphic alleles (2000) (0)
- ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER’S DISEASE (2017) (0)
- Epistasis analysis links immune cascades and cerebral amyloidosis (2015) (0)
- Chapter 4 Apolipoprotein E and lipid mobilization in neuronal membrane remodeling and its relevance to Alzheimer's disease (2002) (0)
- INCREASED PRO-INFLAMMATORY SIGNALING AND EVIDENCE OF ALZHEIMER’S DISEASE PATHOLOGY IN HEALTHY OLDER ADULTS AT RISK FOR AD (2017) (0)
- CDK5RAP2 GENE AND TAU PATHOPHYSIOLOGY IN LATE-ONSET SPORADIC ALZHEIMER’S DISEASE (2017) (0)
- Synergistic Effects of Genetics and Sports Concussions in Aging (2011) (0)
- MSR1 and NEP Are Correlated with Alzheimer’s Disease Amyloid Pathology and Apolipoprotein Alterations (2022) (0)
- Author response: Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease (2021) (0)
- HMG COA REDUCTASE IS A GENETIC MODIFIER FOR RISK, AGE OF ONSET AND ALZHEIMER’S DISEASE’S CONVERSION WHICH MODULATES PATHOLOGY-RELATED AD BIOMARKERS (2017) (0)
- BRAIN ISOPRENOIDS AND ALZHEIMER'S DISEASE (2016) (0)
- 649 Interaction of Estrogen Replacement Therapy (ERT) and Apolipoprotein E (Apo E) status on response to cholinesterase inhibitor therapy in AD (1996) (0)
- Associations between TLR4 Asp299Gly variant and Alzheimer’s-related pathological biomarkers (2015) (0)
- P-8-9 Apolipoprotein E genotype and clinical measures of dementia (1995) (0)
- YEARS TO PARENTAL SYMPTOM ONSET PREDICTS AMYLOID BURDEN IN HEALTHY ELDERLY WITH A PARENTAL HISTORY OF SPORADIC ALZHEIMER DISEASE (2017) (0)
- HIGH CSF TAU IS RELATED TO REDUCED HIPPOCAMPAL VOLUME AND SUBJECTIVE COGNITIVE DECLINE IN HEALTHY ELDERLY WITH AMYLOID PATHOLOGY (2016) (0)
- Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression (2019) (0)
- [BIOLOGICAL DATA IN ACROMEGALY]. (1963) (0)
- THE IMPACT OF TSPO RS6971 POLYMORPHISM IN A CANADIAN NEUROIMAGING STUDY OF NEUROINFLAMMATION (2018) (0)
- GWAS IN AN EASTERN CANADIAN POPULATION ISOLATE LEADS TO NOVEL GENETIC RISK VARIANTS IN GENES ASSOCIATED WITH SYNAPTIC REMODELLING (2014) (0)
- Longitudinal Blood Biomarker Trajectories in Preclinical Alzheimer’s Disease (2022) (0)
- S3-02-03 Disease modification: From etiological hypothesis to clinical testing (2006) (0)
- Pharmaceutical-genetic methods for use in the treatment of diseases of the nervous system (1997) (0)
- EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNORESPONSE (2014) (0)
- Analysis of novel genetic factors associated with tau metabolism in the late-onset form of sporadic Alzheimer's disease (2015) (0)
- NSAIDS FOR AD PREVENTION? NAPROXEN ENTERS THE CNS WITHOUT APPARENT EFFECT ON CSF IMMUNE MARKERS (2019) (0)
- Involvement of paraoxonase 1 (PON-1) genetic variants in Alzheimer pathophysiology (2010) (0)
- Adrenal Glucocorticoids as Modulators of Brain Aging (1993) (0)
- CSF INFLAMMATORY AND LIPID TRANSPORTER PROTEINS PREDICT GREY MATTER DENSITY LONGITUDINAL CHANGES (2016) (0)
- HSV-1 and risk of Alzheimer's disease (1998) (0)
- Assessment of white matter hyperintensity severity using multimodal MRI in Alzheimer’s Disease (2023) (0)
- Apo E and apo E receptor gene expression in the brain of Alzheimer's disease subjects with different apoE genotype (2000) (0)
- HIVEP3 variant is associated with increased amyloid deposition and lower hippocampal volume in cognitively unimpaired subjects. (2022) (0)
- P2-085 Response to brain injury in human apolipoprotein E targeted replacement mice is genotype-specific (2004) (0)
- 1st Sandoz Symposium on the Treatment of Parkinson’s Disease, Vol. 33(suppl 1), 1993 (1993) (0)
- ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER’S DISEASE (2017) (0)
- GENETIC AND ENVIRONMENTAL FACTORS ARE DIFFERENTIALLY RELATED TO Aβ BURDEN IN THE PRESYMPTOMATIC PHASE OF AUTOSOMAL DOMINANT AND SPORADIC ALZHEIMER’S DISEASE (2018) (0)
- The role of IGFBP2 in pre‐symptomatic Alzheimer's disease: a multimodal longitudinal study of cognitively unaffected individuals with a family history of sporadic Alzheimer’s disease (2022) (0)
- IDENTIFICATION OF NOVEL GENETIC RISK VARIANTS FOR ALZHEIMER’S DISEASE IN THE HMGCR GENE LOCUS (2017) (0)
- CSF IMMUNE MARKERS PREDICT DECREASED AD SYMPTOM SEVERITY AND PROGRESSION (2018) (0)
- Clusterin is associated with Alzheimer’s disease biomarkers and cognitive scores in the pre‐symptomatic phase of the disease. (2022) (0)
- FAMILIARITY DEFICITS IN INDIVIDUALS WITH APOE E4: AN MRI INVESTIGATION OF STRUCTURAL CORRELATES (2017) (0)
- EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNO-RESPONSE (2014) (0)
- Characterization of the contactin 5 protein and its risk-associated polymorphic variant throughout the Alzheimer's disease spectrum. (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Judes Poirier?
Judes Poirier is affiliated with the following schools:
